

Enhanced Drug List Updates

April 2021

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
COPAXONE (glatiramer acetate soln prefilled syringe 20 mg/ml)	Brand	Removal, Non-Preferred Status, generics available
COPAXONE (glatiramer acetate soln prefilled syringe 40 mg/ml)	Brand	Removal, Non-Preferred Status, generics available
EPCLUSA (sofosbuvir-velpatasvir tab 200-50 mg)	Brand	Addition, Preferred Status
RETACRIT (epoetin alfa-epbx inj 20000 unit/ml)	Brand	Addition, Preferred Status
RETEVMO (selpercatinib cap 40 mg)	Brand	Addition, Preferred Status
RETEVMO (selpercatinib cap 80 mg)	Brand	Addition, Preferred Status
SYMFI (efavirenz-lamivudine-tenofovir df tab 600-300-300 mg)	Brand	Removal, Non-Preferred Status, generics available
SYMFI LO (efavirenz-lamivudine-tenofovir df tab 400-300-300 mg)	Brand	Removal, Non-Preferred Status, generics available
SYMTUZA (darunavir-cobic-emtricitab-tenofov af tab 800-150-200-10 mg)	Brand	Addition, Preferred Status
TAKHZYRO (lanadelumab-flyo inj 300 mg/2ml (150 mg/ml))	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.